Appendix 4D and Half Year Results H1 2020

Imagion Biosystems has announced Appendix 4D and Half Year Results H1 2020. These are the highlights: Significant advancements towards initiating…


IBX Secures Additional Capital — Shareholders Exercise Options

Imagion Biosystems Limited announce that it has received $1.29m for the exercise of unlisted options issued under the terms of the 2018 Rights Issue…


Phase I Study Update: Submission for Ethics Approval Filed

Imagion Biosystems is pleased to provide an update with regard to its plans to undertake a Phase I study of its first MagSense™ product for the detection of…


Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001

Imagion Biosystems Limited gives notice that, on 4 August 2020 the Company issued 112,111,111 fully paid ordinary shares (Shares) as well as 6,500,000…


Quarterly Activity Report and Appendix C

Quarterly Activity Report – Period ending 30 June 2020 Q2 Highlights: Company announces plans for the Phase I first-in-human study to be undertaken in…


Proposed Issue of Securities — IBX

Imagion Biosystems Limited has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.


Proposed Issue of Securities — IBXOA

Imagion Biosystems has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.


IBX Raises $5M in Oversubscribed Placement

$5M raised in an oversubscribed placement at 4.5c per share – equivalent to 30 day VWAP, and a 33.9% premium to 60 day VWAP. Strongly supported by existing…


Appendix 2A

The application for quotation (Appendix 2A) for listed options (IBCOA) was released to the market. Read Appendix 2A.


Trading Halt

The securities of Imagion Biosystems Limited (‘IBX’) will be placed in trading halt at the request of IBX, pending it releasing an announcement regarding a…